This Pharmacist’s Manual has been prepared by the Drug Enforcement Administration, Diversion Control Division, as a guide to assist...
Reports
Federal Register Notice: Withdrawal of proposed placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT in Schedule I
/ /
As of Wednesday, July 27, 2022, the DEA has withdrawn a proposed rule that was published in the Federal...
The objective of this report is to provide updated guidance in developing an appropriate analytical scope of testing for...
From June 20, 2022 to July 20, 2022, opioid-related 911 responses were reported in 1,188 incident counties in 43...
Trend Reports – Q2 2022 – NPS Benzodiazepines, NPS Opioids, NPS Stimulants & Hallucinogens, and Synthetic Cannabinoids
/ /
NPS Discovery published their Q2 2022 NPS Trend Reports. The most prevalent NPS in Q2 2022 by class included,...
The Canadian Centre on Substance Use and Addiction (CCSA) in partnership with the Canadian Community Epidemiology Network on Drug...
A Panel Study of the Effect of Cannabis Use on Mental Health, Depression and Suicide in the 50 States
/ /
A first of its kind nationwide study, commissioned by Drug Free America Foundation, Inc. and Johnny’s Ambassadors, finds more...
The 2022 World Drug Report provides a global overview of the supply and demand of opiates, cocaine, cannabis, amphetamine-type...
Telehealth and Substance Use Disorder Services in the Era of Covid 19: Review and Recommendations
/ /
On June 22, the Office of National Drug Control Policy announced the release of LAPPA’s white paper, Telehealth and...
The European Drug Report (EDR) 2022 arrives at a time when recent major global events have impacted profoundly on...
Trending Reports
-
2022 Pharmacist Manual – DEA August 7, 2022
-
Federal Register Notice: Withdrawal of proposed placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT in Schedule I July 27, 2022
-
Recommended Scope for NPS Testing in the United States: Q2 2022 July 25, 2022
-
Opioid overdose-related 911 EMS responses per 10k population, June 20, 2022 – July 20, 2022 July 21, 2022
-
Trend Reports – Q2 2022 – NPS Benzodiazepines, NPS Opioids, NPS Stimulants & Hallucinogens, and Synthetic Cannabinoids July 12, 2022